Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024175 | 1.00 | PPARA (0.64) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL28595041 | 1.00 | PPARA (0.64) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL5827383 | 0.94 | PPARA (0.62) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL21837541 | 0.94 | PPARA (0.58) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL21837546 | 0.94 | PPARA (0.58) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL7319742 | 0.91 | TACR1 (0.62) | CTSKCTSLCTSSTACR1CTSB | |
| SCHEMBL4391662 | 0.90 | PPARA (0.57) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL1170973 | 0.89 | CTSK (0.56) | PPARAFOLH1PPARGCTSKCTSL | |
| SCHEMBL31456194 | 0.89 | CTSK (0.60) | PPARAFOLH1CTSKCTSLCTSS | |
| SCHEMBL16351361 | 0.88 | KYNU (0.62) | PPARACTSKCTSLCTSSTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672582-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12421185-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2025-09-23 | — | — | US | disclosed |
| US-11529338-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| CN-107709301-B | Pyrazole derivative or pharmacologically acceptable salt thereof | 橘生药品工业株式会社 | 2021-06-22 | — | — | CN | disclosed |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2021-06-03 | — | — | US | disclosed |
| US-10927070-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3319970-B1 | PYRIDO-OXAZINONE DERIVATIVES AS TNAP INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2019-06-27 | — | — | US | disclosed |
| EP-1147095-B1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1147095-A1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| CN-1293663-A | 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamix acids as matrix metal-protease | AMERICAN CYANAMID CO (US) | 2001-05-02 | — | — | CN | disclosed |
| EP-1051407-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000044730-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |
| US-4564471-A | N-/BENZYLOXYCARBONYL/ASPARTYLPHENYLALANINE | AJINOMOTO CO., INC. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0027319-A2 | Method for reductive elimination of protecting groups and preparative process using such method | AJINOMOTO CO., INC. (JP) | 1981-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421185-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | PPARA 2140/4885FOLH1 25/4885PPARG 1746/4885 |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, RNASE1, TP53 | PPARA 2140/4885FOLH1 25/4885PPARG 1746/4885 |
| US-11529338-B2 | Compositions and methods for treating cancer | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | PPARA 3070/4885FOLH1 416/4885PPARG 2340/4885 |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | PPARA 3070/4885FOLH1 416/4885PPARG 2340/4885 |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, TP53, RNASE1 | PPARA 2218/4885FOLH1 55/4885PPARG 1924/4885 |
| US-10927070-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | PPARA 2140/4885FOLH1 25/4885PPARG 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.